Side-by-side · Research reference
CartalaxvsMazdutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED10/32 cited
BPhase 3HUMAN-REVIEWED19/62 cited
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
01Mechanism of Action
Parameter
Cartalax
Mazdutide
Primary target
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
GLP-1 receptor and glucagon receptorAbdul 2026Elmendorf 2026
Pathway
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026Abulehia 2026
Downstream effect
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D
Feedback intact?
—
Yes — physiological receptor-mediated signaling preserved
Origin
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity
Antibody development
—
—
02Dosage Protocols
Parameter
Cartalax
Mazdutide
Animal model dose
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
—
Human dosing
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
—
Phase 2 studied dose
—
Dose escalation
—
3 mg → 6 mg → 9 mg (titration schedule in trials)
Gradual escalation to minimize GI side effects.
Duration (trials)
—
24–48 weeks
Population
—
Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities
03Metabolic / Fat Loss Evidence
Parameter
Cartalax
Mazdutide
Fat loss evidence
None — primary target is cartilage and bone tissue, not adipose
—
Percentage body weight loss
—
12.4% (pooled meta-analysis, 9 mg dose)
95% CI: -16.15% to -8.68%, random-effects model.Azam 2026
Responder rate (≥10% loss)
—
Not explicitly reported in available abstracts
Visceral fat
—
Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)
Glycemic improvement
—
HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)
Key publications
—
Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026
04Side Effects & Safety
Parameter
Cartalax
Mazdutide
Documented adverse effects
None reported in indexed animal studies
—
Human safety data
Not available in PubMed-indexed literature
—
Gastrointestinal symptoms
—
Nausea, vomiting, diarrhea (most common, GLP-1 effect)
Injection site reactions
—
Erythema, pruritus, local discomfort
Hypoglycemia
—
Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas
Cardiovascular effects
—
Increased heart rate (glucagon effect, transient)
Pancreatitis risk
—
Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain
Thyroid C-cell tumors
—
Black box warning for GLP-1 class (rodent data); human relevance unclear
Gallbladder disease
—
Cholelithiasis, cholecystitis (rapid weight loss effect)
Tolerability
—
Generally well-tolerated; GI effects diminish with dose titration
Absolute Contraindications
Cartalax
- ·Unknown due to lack of human clinical trial data
Mazdutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- ·Hypersensitivity to mazdutide or excipients
- ·Pregnancy
Relative Contraindications
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
Mazdutide
- ·History of pancreatitis
- ·Severe gastroparesis or GI motility disorders
- ·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
- ·Renal impairment (limited data, use with caution)
05Administration Protocol
Parameter
Cartalax
Mazdutide
1. Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.
2. Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.
3. Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.
4. Storage
—
Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.
5. Needle technique
—
Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.